Evelo Biosciences Completes Enrollment to Interim Target in Phase 2 Trial Evaluating EDP1815 for the Treatment of Psoriasis
03 déc. 2020 07h00 HE
|
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., Dec. 03, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines which act...
Evelo Biosciences Presents New Preclinical Data for Anti-Tumor Effects of Orally Delivered Microbial Extracellular Vesicles at the SITC 35th Anniversary Annual Meeting
09 nov. 2020 08h00 HE
|
Evelo Biosciences, Inc.
-- EDP1908 demonstrates potent anti-tumor effects in murine models of cancer -- -- Oral extracellular vesicles have potential to be a completely novel mechanism of I/O therapy -- CAMBRIDGE, Mass.,...
Evelo Biosciences Reports Third Quarter 2020 Financial Results and Business Highlights
29 oct. 2020 07h00 HE
|
Evelo Biosciences, Inc.
-- Treated first patients in Phase 2 dose-ranging trial for EDP1815 in psoriasis ---- Six clinical readouts in psoriasis, atopic dermatitis, COVID-19, and breast cancer expected over next 3-9 months...
Evelo Biosciences to Report Third Quarter 2020 Financial Results on Thursday, October 29, 2020
22 oct. 2020 16h01 HE
|
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting...
Evelo Biosciences to Host Key Opinion Leader Discussion Focused on the Unmet Need in Psoriasis and Atopic Dermatitis and the Potential Opportunity for EDP1815
15 oct. 2020 07h00 HE
|
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting...
Evelo Biosciences Completes Enrollment in Phase 1b Clinical Trial Cohort Evaluating EDP1815 in Atopic Dermatitis
14 oct. 2020 07h00 HE
|
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., Oct. 14, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting...
Evelo Biosciences Treats First Patients in Phase 2 Dose-Ranging Trial of EDP1815 for the Treatment of Psoriasis
13 oct. 2020 07h00 HE
|
Evelo Biosciences, Inc.
– Interim data expected by mid-2021 – CAMBRIDGE, Mass., Oct. 13, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of...
Evelo Biosciences Appoints Julie Carretero as Chief People Officer
14 sept. 2020 07h06 HE
|
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting...
Evelo Biosciences to Participate in Upcoming Investor Conferences in September
08 sept. 2020 07h00 HE
|
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting...
Evelo Biosciences Reports Second Quarter 2020 Financial Results and Business Highlights
30 juil. 2020 07h00 HE
|
Evelo Biosciences, Inc.
– FDA authorization of IND for Phase 2 trial of EDP1815 in COVID-19 in the U.S.; data expected in 4Q 2020 ––Achieved regulatory and ethics authorization for Phase 2 dose ranging trial for EDP1815 in...